Corona Remedies Ltd. Address IPO Details: Price, Dates & Financials

Pre-issue shareholding: 61,160,088 shares. Post-issue shareholding: 61,160,088 shares.

Corona Remedies Ltd. Address IPO is a Offer For Sale issue. Issue type: Bookbuilding IPO. Face value is ₹10.

The UPI mandate for Corona Remedies Ltd. Address IPO needs to be accepted by 10 Dec 2025. Approve the mandate request in your UPI app before the deadline, otherwise your bid may be rejected.

The Red Herring Prospectus (RHP) of Corona Remedies Ltd. Address IPO is available on the website of the lead manager and the stock exchange (NSE & BSE) — see the lead manager links on the main page.

The DRHP is the initial offer document filed for regulatory review, while the RHP includes updated disclosures, final issue details, and the price band (when announced). Comparing both documents helps investors identify changes in the Corona Remedies Ltd. Address IPO's financial information, risks, and offer terms before investing in the Corona Remedies Ltd. Address IPO. Reviewing both documents provides a clearer understanding of the Corona Remedies Ltd. Address IPO before making an investment decision.

The DRHP and RHP of the Corona Remedies Ltd. Address IPO disclose potential risks related to the company's business, financial performance, legal matters, and industry conditions. Reviewing these documents helps investors identify potential concerns about the Corona Remedies Ltd. Address IPO, evaluate the Corona Remedies Ltd. Address IPO's risk factors, and make a more informed decision before investing in the Corona Remedies Ltd. Address IPO.